Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 284 | 75 | 425 | 147 |
| Operating expenses: | ||||
| Research and development (1) | 71,577 | 86,626 | 149,208 | 163,461 |
| Selling, general and administrative | 54,975 | 20,216 | 93,654 | 37,319 |
| Total operating expenses | 126,552 | 106,842 | 242,862 | 200,780 |
| Loss from operations | (126,268) | (106,767) | (242,437) | (200,633) |
| Other income (expense), net: | ||||
| Interest income | 8,490 | 6,546 | 16,362 | 14,086 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s SG&A?
- Viridian Therapeutics, Inc. (VRDN) reported SG&A of $54.98M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s SG&A changed year-over-year?
- Viridian Therapeutics, Inc.'s SG&A increased by 171.9% year-over-year, from $20.22M to $54.98M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Viridian Therapeutics, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude